Ovarian carcinomas often overexpress anti-apoptotic proteins such as BCL-XL [17] and MCL1 [18] and thereby shift the balance toward survival, which provides them with a major advantage in protecting themselves from chemotherapeutic agents [17], [19], [20]. This evidence concerns the gene BCL2L1 and ovarian carcinoma.